Lantheus Holdings to Host Fourth Quarter and Full Year 2020 Earnings Conference Call and Webcast on February 25, 2020 at 4:30 p.m. Eastern Time
Lantheus Holdings, Inc. (NASDAQ: LNTH) will host a conference call on February 25, 2021, at 4:30 p.m. ET to discuss its financial results for Q4 and the full year of 2020. The call can be accessed via telephone or through a live webcast at their website. Lantheus is recognized for its innovative imaging diagnostics and therapeutic solutions, offering products like DEFINITY®, TechneLite®, AZEDRA®, and RELISTOR®, aimed at serious medical conditions.
- Announcement of a conference call to discuss financial and operational results, indicating transparency and investor engagement.
- None.
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 4:30 p.m. ET on Thursday, February 25, 2021, to discuss its financial and operating results for the fourth quarter and full year of 2020.
To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1‑678-509-7599 (international callers) and provide passcode 5247866. A live webcast will also be available in the Investors section of the Company’s website at www.lantheus.com.
A replay of the webcast will be available in the Investors section of the Company’s website approximately two hours after completion of the call and will be archived for 30 days.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow™ serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005736/en/
FAQ
When will Lantheus Holdings discuss its Q4 2020 financial results?
How can I listen to the Lantheus Holdings conference call?
What products does Lantheus Holdings offer?
Where is Lantheus Holdings headquartered?
